Nov 18, 2021 / 04:00PM GMT
Barbara Cano -
Thank you very much for joining us today from the New York Times Building in New York. Earlier this morning, Genomma Lab, and Oramed subsidiary, Oravax Medical, announced the landmark agreement for Genomma Lab to develop and commercialize Oravax's oral COVID-19 vaccine candidate initially in Mexico to ultimately open the gateways throughout Latin America. Manufacturing will also be assessed. I'm joined by Nadav Kidron, CEO of Oramed Pharmaceuticals and the Chairman of Oravax; and Rodrigo Herrera, Chairman of Genomma Lab, will discuss key highlights of this announcement. We will begin the program with a short video about Oravax to give you a better sense of the company and tremendous potential of the partnership. Mr. Kidron will then follow with his remarks. Oravax's oral vaccine technology is based on an oral delivery platform for injectable medications developed by Dr. Miriam Kidron, Oramed's CSO; and by Nobel Laureate Professor Avram Hershko. Their technology is now being used for their oral insulin candidate currently in Phase III trials and has been safely dosed thousands of times. Mr. Kidron
Genomma Lab Internacional SAB de CV & Oramed Pharmaceuticals Inc & Oravax Medical Inc Joint Venture Press Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers